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Uncoupling proteins (UCPs) are mitochondrial membrane transporters involved in the control of energy conversion in mitochon-
dria. Experimental and genetic evidence relate dysfunctions of UCPs with metabolic syndrome and obesity. The PPAR subtypes
mediate to a large extent the transcriptional regulation of the UCP genes, with a distinct relevance depending on the UCP gene
and the tissue in which it is expressed. UCP1 gene is under the dual control of PPARγ and PPARα in relation to brown adipocyte
diﬀerentiation and lipid oxidation, respectively. UCP3 gene is regulated by PPARα and PPARδ in the muscle, heart, and adipose
tissues. UCP2 gene is also under the control of PPARs even in tissues in which it is the predominantly expressed UCP (eg, the
pancreas and liver). This review summarizes the current understanding of the role of PPARs in UCPs gene expression in normal
conditions and also in the context of type-2 diabetes or obesity.
Copyright © 2007 Francesc Villarroya et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
CURRENT KNOWLEDGE OF THE BIOLOGY OF
MITOCHONDRIAL UNCOUPLING PROTEINS
Uncoupling proteins (UCPs) are mitochondrial transporters
present in the inner mitochondrial membrane. The ﬁrst
member of the family, UCP1, is expressed in brown adipo-
cytes and it confers on brown adipose tissue its thermogenic
capacity. UCP1 confers to the mitochondrial inner mem-
brane an enhanced conductivity to protons, thus resulting
in the uncoupling of the respiratory chain and heat produc-
tion. This action of UCP1 in brown adipose tissue consti-
tutesthemainmolecularbasisfornonshiveringthermogene-
sisinrodentsinresponsetocoldexposureanddiet.Thether-
mogenic activity of brown fat is mainly regulated by nore-
pinephrine released from the sympathetic nervous system
innervating the tissue, acting through β-adrenergic, cAMP-
dependent pathways. Accumulating pieces of evidence over
more than two decades have indicated that energy expendi-
ture processes elicited by UCP1 are involved in the control of
energy balance, and that UCP1 activity in brown adipose tis-
sue may provide the basis for diet-induced thermogenesis. In
fact, obesity models in rodents are in most cases associated
with low levels and activity of UCP1 in brown fat. Less clear
is the role of UCP1 in human obesity, taking into account
the residual amounts of brown adipocytes in adult humans.
However, sensitive methodologies based on RT-PCR have re-
vealed that remnant UCP1-expressing cells are widespread
among the white adipose depots of human adults. Further-
more,geneticevidenceoftheassociationofUCP1genepoly-
morphisms with disturbances of body weight in humans
keeps the debate on the physiological role of UCP1 in adults
ongoing [1]. The discovery in 1997 of two proteins highly
similar to UCP1, named UCP2 and UCP3, with a high level
of expression in humans, suggested the possibility that the
role of UCP1 in the control of energy expenditure was played
in humans by these two novel proteins. A decade later, the
precise roles of UCP2 and UCP3 remain a matter of debate
[2–4]. Like UCP1, UCP2 and UCP3 lower the mitochondrial
membrane protomotive potential, but it is unclear whether
dissipation of metabolic energy as heat is their primary bi-
ological function. However, their capacity to protect against
obesity has been demonstrated, at least for UCP3, in experi-
mental settings based on transgenic mice overexpressing the
p r o t e i ni nm u s c l e[ 5]. The speciﬁc involvement of UCP2 and
UCP3 in the control of reactive oxygen species production or
infattyacidoxidationhasbeenproposed.Inanycase,genetic
approaches in humans have highlighted the involvement of
both proteins in metabolic regulation and in associated dis-
turbances such as diabetes and obesity [6].
The transcriptional control of gene expression of UCP1,
UCP3, and, to a minor extent, of UCP2 determines the levels
ofthecorrespondingproteinsintissuesandcells.Researchin2 PPAR Research
recent years has identiﬁed peroxisome proliferator-activated
receptors (PPARs) as pivotal actors in the control of tran-
scription of the UCP genes. As well as providing a basis for
insight into the regulation of transcription of UCP genes in
response to physiological ligands of PPARs, an understand-
ing of the precise mechanisms and the PPAR subtypes in-
volved in this regulation would provide the possibility of
the development of pharmacological approaches to modu-
late the levels of UCPs, given the availability of drugs act-
ing selectively on PPAR subtypes, such as ﬁbrates and thia-
zolidinediones.
PPARS IN THE CONTROL OF THE UCP1 GENE,
BROWN ADIPOCYTE DIFFERENTIATION, AND
ENERGY EXPENDITURE
TheUCP1geneisatargetofdualregulationby
PPARγ andPPARαinbrownadiposetissue
Brown adipose tissue and white adipose tissue have dis-
tinct metabolic functions. In contrast to the role of white
adipose tissue as a site of energy storage, brown fat dissi-
pates metabolic energy as heat, thus promoting energy ex-
penditure. Whereas large amounts of white adipose tissue
are associated with obesity, the development of high levels
as well as high activity of brown adipose tissue is usually as-
sociated with a reduction in body weight. However, brown
adipocytes and white adipocytes share multiple metabolic
features and gene expression patterns, such as those related
to lipid storage. They also share key transcriptional factors
that mediate their diﬀerentiation process; namely, PPARγ
and CCAAT-enhancer binding-protein α (C/EBPα). In fact,
all three PPARs are expressed in brown fat [7], and their rela-
tiverolesinregulatingbrownfatthermogenesisandinUCP1
gene expression will be discussed.
PPARγ is highly expressed both in brown and white
adipocytes. Activation of PPARγ induces brown and white
adipocytes diﬀerentiation by regulating the expression of
genes involved in adipogenesis and lipid storage, whereas
PPARγ-null cells cannot diﬀerentiate into adipocytes [8].
Mice that speciﬁcally lack PPARγ in adipose tissues have re-
duced adiposity and compromised survival of mature brown
and white adipocytes [9, 10]. Furthermore, the transcription
factor C/EBPα, which is necessary for white adipose tissue
development in mice [11], also has a critical role in brown
adipocyte diﬀerentiation during perinatal development, al-
though later on C/EBPβ and C/EBPδ can functionally re-
place C/EBPα [12]. C/EBPα (and also C/EBPβ and C/EBPδ)
function synergistically with PPARγ to regulate genes ex-
pressed in both brown and white adipocytes [13], but also
the brown fat-speciﬁc UCP1 gene [14–16]. In fact, the tran-
scription of the UCP1 gene is tightly regulated during brown
adipocyte diﬀerentiation and in response to thermogenic
activation. The 5 -ﬂanking regions of the rat, mouse, and
human UCP1 genes share a common genomic structure: a
proximal regulatory region and an upstream enhancer lo-
cated at −2kb for review , see [17]. The proximal regula-
tory promoter contains C/EBP-regulated sites and the main
cAMP-regulatory element [14, 18, 19]. The UCP1 gene dis-
tal enhancer includes a complex organization of nuclear re-
ceptorbindingsiteswhichmediatethetranscriptionalactiva-
tion of the UCP1 gene by retinoids, thyroid hormones, PPAR
agonists, and also cAMP, probably through induction of the
PPAR coactivator-1α (PGC-1α)[ 18, 20–25].
PGC-1α was ﬁrst identiﬁed as a PPARγ-interacting pro-
tein displaying preferential expression in mature brown
adipocytes rather than white adipocytes [26]. The expres-
sion of PGC-1α is highly induced in brown fat in response
to thermogenic activation via cAMP-signaling pathways
[15,26].PGC-1αhasbeenproposedtobeessentialforbrown
adipocyte diﬀerentiation and induction of the UCP1 gene
[26]. As previously mentioned, UCP1 is uniquely present in
brown adipocytes, where it is highly expressed as it may ac-
count for up to 8% of the mitochondrial protein (and mi-
tochondrial protein represents 50% of total protein). Brown
adipocytes, unlike white adipocytes, also possess powerful
fatty acid oxidation machinery as evidenced by the abun-
dance of mitochondria, a high level of expression of PPARα
and a high activity of fatty acid oxidation pathways. PGC-
1α can activate all of these key components of the thermo-
genic program through coactivation of PPARγ and PPARα
(see below), or of transcription factors such as nuclear res-
piratory factor-1 [24, 26, 27]. In this way, forced expression
of PGC-1α in white adipocytes induces mitochondrial bio-
genesis and expression of UCP1 [26–28]. In contrast, PGC-
1β, another coactivator highly similar to PGC-1α, is only in-
volved in controlling mitochondrial biogenesis together with
PGC-1α[29].Furthermore,lossofPGC-1αdoesnotalter“in
vitro” brown adipocyte diﬀerentiation but completely blunts
the thermogenic induction via cAMP of the UCP1 gene and
other thermogenic and mitochondrial genes [29].
Thiazolidinediones, drugs speciﬁcally activating PPARγ,
have an overall eﬀect of promoting adipogenesis, but have
also been reported to induce mitochondrial biogenesis [30]
besides their direct eﬀect upon UCP1 transcription via
PPARγ activation (see above). This induction of “brown
fat-like” features by thiazolidinediones entails direct upreg-
ulation of transcription of the PGC1α gene by PPARγ in
adipocytes [31]. This induction of PGC1α is ampliﬁed by an
autoregulatory loop mediated by the coactivation of PPARγ
action on PGC1α gene transcription by PGC1α itself [31],
similarly to PGC1α coactivation with PPARγ in the promot-
ers of other genes such as UCP1 [24].
In summary, the available data point to a function of
PGC1α in orchestrating the regulation of mitochondrial bio-
genesis and UCP1 gene induction during brown adipocyte
diﬀerentiation. Regarding UCP1 gene transcription, coacti-
vation with PPARγ is probably involved in mediating this
eﬀect of PGC-1α. However, the thermogenic activation of
mature brown adipocytes results in a negative regulation of
PPARγ, thus suggesting that PPARγ may not be essential
for UCP1 gene expression in already diﬀerentiated brown
adipocytes recently reviewed in [32].
Since PPARα is preferentially expressed in brown
adipocytes as compared to white adipocytes, it can be ex-
pected that it is mainly through PPARα that the UCP1 gene
is induced in mature brown adipocytes. Agonists of eitherFrancesc Villarroya et al. 3
PPARγ or PPARα can induce UCP1 gene expression both
in brown fat “in vivo” and in brown adipocytes “in vitro”
[24, 33, 34]. Furthermore, the PPAR-response element of the
UCP1 gene enhancer can bind either PPARγ or PPARα [24].
PGC-1α also coactivates PPARα-dependent regulation of the
UCP1 gene [24]. Although basal expression of UCP1 mRNA
in brown fat from PPARα- n u l lm i c ei sn o ta l t e r e d[ 35], there
isanimpairedactivationofUCP1geneexpressioninPPARα-
null mice in several physiological situations associated with
coldstress(ourunpublishedobservations).Furthermore,ge-
netic analyses revealed that PPARα gene expression is associ-
ated with UCP1 gene induction [36].
Likewise, PGC1α can cooperate with PPARα in the tran-
scriptional control of genes for fatty acid catabolism in
brown fat. Activation of brown fat thermogenesis, which
is mediated by cAMP-dependent pathways, rapidly induces
lipolysis of the stored triglycerides. Released fatty acids, in
addition to being the major substrate for thermogenesis and
the inducers of UCP1 uncoupling activity through direct in-
teraction with the UCP1 protein in the inner mitochondrial
membrane [37], may also act as PPAR-activators. Thus, the
PGC-1α/PPARα interaction can coordinately regulate gene
expression required for active thermogenesis, including fatty
acid oxidation, in mature brown adipocytes.
Whether PPARδ, the third PPAR subtype, can also play
a direct role in the regulation of UCP1 gene expression has
not been clearly elucidated. Transgenic mice overexpressing
an activeformof PPARδ in adipose tissuesdisplayed reduced
accumulation of triglycerides both in white fat and brown
fat [38]. However, only the size of white depots was reduced.
UCP1 and genes involved in fatty acid catabolism were mod-
erately induced in brown fat and highly induced in white
fat in these mice. However, neither induction of the endoge-
nousUCP1geneinprimarymurinebrownadipocytesbythe
PPARδ-speciﬁc GW501516 ligand nor PPARδ-dependent
regulation of the UCP1 gene promoter has been observed in
brownadipocytesinculture(ourunpublishedobservations).
Rexinoid-dependentUCP1generegulationin
brownadiposetissue
Both white and brown adipose tissues contain retinoic acid
receptor (RAR) and retinoid X receptor (RXR) subtypes
with distinct relative abundances. Retinoic- and rexinoid-
dependent pathways of regulation in adipose tissues have
previously been extensively reviewed [39, 40].
Retinoic acid acting via RAR has long been recognized
as a potent inhibitor of the diﬀerentiation of preadipocytes
into white and brown adipocytes [41, 42]. However,
when retinoic acid acts upon already diﬀerentiated brown
adipocytes, it dramatically increases UCP1 gene expression
through a direct transcriptional eﬀect (see below) [21]. The
action of retinoic acid in promoting UCP1 gene expression
has been conﬁrmed “in vivo” by pharmacological treatment
and by vitamin A supplementation of the diet [43, 44]. How-
ever,thebiologicalsigniﬁcanceofthispowerfulretinoicacid-
dependent regulation of the UCP1 gene in response to RAR
activation remains unknown.
Retinoic acid stimulates UCP1 gene transcription
through a complex “retinoid-responsive region” in the dis-
tal enhancers of the rat or human UCP1 genes [21, 23]. Both
RAR- and RXR-binding sites in the enhancer contribute to
theretinoicacideﬀects[45].InductionofUCP1geneexpres-
sionbyretinoicaciddoesnotrequirePGC1α[29].TheUCP1
gene is a direct target of speciﬁc RXR activators through
RXR-containing heterodimers that bind to the enhancer re-
gion of the UCP1 gene [45]. Phytanic acid (3,7,11,15-
tetramethylhexadecanoic acid), which is a derivative of the
phytol side chain of chlorophyll, has been reported to be a
natural ligand of RXR subtypes [46], but also to be a di-
rect activator of PPARα [47]. Phytanic acid induces UCP1
gene expression through the RXR-binding sites in the UCP1
gene enhancer [48].This may be closely related to thermo-
genic activation, as phytanic acid accumulates in the brown
adipose tissue fat stores and is released as a free acid when
lipolysis is active in the tissue owing to thermogenic stim-
uli. In these conditions, phytanic acid can act as a signaling
molecule linking lipolysis with enhanced synthesis of UCP1
protein to favor thermogenesis [49].
In summary, as depicted in Figure 1, the expression of
the UCP1 gene is directly regulated by PPARs in association
with adipogenic diﬀerentiation (via PPARγ) and in coordi-
nation with induction of gene expression for the fatty acid
oxidation required for active thermogenesis (via PPARα).
Whether these PPAR/rexinoid-dependent pathways can af-
fect energy expenditure in adult humans remains to be de-
termined. Although the amounts of UCP1-expressing brown
adipocytes are low in adult humans, UCP1 gene expression
canbereactivatedinseveralconditionssuchashighexposure
to catecholamines released by pheochromocytomas [50], or
chronic treatment with antiretroviral drugs [51]. Future re-
search will be required to determine whether PPAR agonists
and/or retinoids cause similar activation, considering that
they are powerful activators of human UCP1 gene transcrip-
tion “in vitro” [23].
PPARα AND PPARδ CONTROL UCP3 GENE
EXPRESSION IN SKELETAL MUSCLE
AND HEART
FreefattyacidsaremajorinducersofUCP3gene
expressioninskeletalmuscleandheart
Initial studies on the regulation of UCP3 gene expression
in skeletal muscle, its main site of expression, revealed that
transcript levels of UCP3 were dramatically inﬂuenced by
the availability of free fatty acids to the tissue both in ro-
dents and humans. This explained the rise in UCP3 mRNA
inmuscleafterstarvation,anobservationinitiallyconsidered
as a paradox at the time when UCP3 was expected to have a
role similar to UCP1 in the promotion of energy expenditure
[52]. Today, we know that UCP3 mRNA levels are system-
atically upregulated in association with any physiological or
experimental rise in circulating free fatty acids, either when
they originate from lipolysis in white fat (starvation or exer-
cise) or from the diet (high-fat diet) [53–55]. The increase4 PPAR Research
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Figure 1: Schematic representation of the regulation of UCP1 gene expression by ligand-dependent activation of PPARα and PPARγ,a n d
coactivationbyPGC-1α.ThediagramshowsthePPARresponseelementintheratUCP1geneenhancer(24).Majorfeaturesofthetranscrip-
tional regulation of the mouse and human UCP1 genes appear to be similar (16,23). During brown adipocyte diﬀerentiation, adipogenic
signals activate transcription of the UCP1 gene through PPARγ and coactivation by PGC-1α, in concert with overall induction of adipocyte
diﬀerentiation towards the brown fat lineage. In response to thermogenic simuli on mature brown adipocytes, activation of PPARα by
lipolysis-derived fatty acids contributes to the coordination of UCP1 gene transcription (thermogenesis) with the lipid oxidation pathways
providing metabolic fuel for oxidation.
in free fatty acids due to the initiation of milk (a fat-rich
diet) intake also causes a dramatic rise in UCP3 mRNA af-
ter birth [56]. The opposite situation also occurs: a drop in
free fatty acid levels such as that occurring in lactating dams
is associated with a decrease in UCP3 transcript in muscle
[57]. Studies in humans conﬁrmed the regulation of UCP3
mRNA expression by fatty acids in human skeletal muscle
and the heart [58, 59].
Several studies have indicated that favoring the intracel-
lular presence of free fatty acids stimulates UCP3 gene ex-
pression. Thus, overexpression of lipoprotein lipase in mus-
cle leads to a rise in UCP3 mRNA, surely due to the en-
hancement in local free fatty acid availability via hydrolysis
of triglycerides [60]. Moreover, when intracellular fatty acid
oxidation is blocked by the use of etomoxir, an inhibitor of
carnitine palmitoyl transferase-1, UCP3 transcript levels rise
also [61].
PPARαandPPARδ,mediatorsofthefattyacid-
dependentcontrolofUCP3transcriptionin
skeletalmuscleandheart
Multiple lines of evidence have shown that PPARα plays a
major role in the induction of the UCP3 gene in response to
fatty acids. Acute treatment of mice pups with the speciﬁc
activator of PPARα Wy 14643 mimics the postnatal skele-
tal muscle UCP3 gene induction caused by fatty acids com-
ing from milk [56]. A single injection of this drug to adult
lactating mice also induces UCP3 mRNA expression [57].
Moreover, PPARα-null mice show reduced levels of UCP3
gene expression and impaired response to starvation in the
heart [62–64]. This does not occur in skeletal muscle in
adult PPARα-null mice, possibly due to compensatory up-
regulation of the UCP3 gene by PPARδ (see below). How-
ever, PPARα-null mice neonates display lowered UCP3 gene
expression both in skeletal muscle and in the heart [65]. On
the other hand, transcriptomic analysis of muscle or heart
from transgenic mice which overexpress PPARα speciﬁcally
inthesetissuesrevealedthatUCP3mRNAisamongthemost
intensely induced gene transcripts [66, 67]. This occurs in
concert with induction of many other genes involved in fatty
acid oxidation. Thus, the UCP3 gene appears to be part of
the cluster of PPARα-regulated, fatty acid catabolism-related
genes in the muscle and heart. Regardless of the information
provided by experimental approaches directly addressing the
issue of the biological function of UCP3, these observations
strongly suggest that UCP3 function is likely to be related to
fatty acid metabolism in these tissues.
Despite all these lines of evidence, reports on the eﬀects
of chronic treatment with ﬁbrates, which are potential acti-
vators of PPARα in muscle, have led to variable results; from
unchanged expression of the UCP3 gene using Wy 14643Francesc Villarroya et al. 5
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[33] to upregulation using bezaﬁbrate [68]. The reasons for
this variability in response to chronic treatment as opposed
to the systematic upregulation observed in acute, single-
injection treatment with ﬁbrates are unclear. Perhaps the hy-
polipidemic consequences of chronic ﬁbrate treatment, in-
cluding reductions in the levels of circulating fatty acids,
may counteract the direct positive eﬀects of the drugs on the
UCP3 gene.
Studies in cell culture have been also less conclusive in
relation to the role of PPARα in the control of UCP3 gene ex-
pression. Myogenic cells in culture express very low levels of
UCP3 relative to muscle “in vivo” [69] and, when they were
exposed to ﬁbrates, PPARδ-dependent activation appears to
have a more powerful eﬀect on UCP3 gene induction than
does PPARα activation [70, 71]. However, the signiﬁcance of
these observations for “in vivo” regulation of the UCP3 gene
is unclear because myogenic cell lines such as C2C12 or L6
show abnormally reduced expression of PPARα relative to
that in skeletal muscle. Thus, a low sensitivity of the UCP3
gene (and other PPARα-target genes) to PPARα activators is
anticipated in such cell systems [71, 72].
The capacity of PPARδ to activate UCP3 in muscle and
the heart has been demonstrated also using “in vivo” ap-
proaches. Similar to PPARα overexpressing mouse models,
overexpression of PPARδ in muscle obtained via transgenic
micerevealedthatUCP3isamongthegenesmostsensitiveto
induction[73,74].Moreover,amousemodeloftargeteddis-
ruption of PPARδ speciﬁcally in the heart revealed a reduc-
tion in UCP3 levels [75]. The recent availability of drugs act-
ing speciﬁcally on PPARδ conﬁrmed “in vivo” and “in vitro”
the sensitivity of the UCP3 gene to activation via PPARδ.
Thus, chronic treatment of mice with a PPARδ activator in-
duces UCP3 gene expression in concert with other genes of
lipid metabolism [76, 77]. Therefore, the dual regulation of
the UCP3 gene by PPARα and PPARδ in muscle and heart
is shared by many genes involved in fatty acid oxidation and
again suggests the involvement of UCP3 in biological func-
tions related to fatty acid catabolism.
Most of the above conclusions arising from studies on
experimental animals or human volunteers have been con-
ﬁrmed by studies directlyaddressing the transcriptional con-
trol of the human and mouse UCP3 gene promoter in
muscle cells. Both PPARα and PPARδ activate the UCP3
gene promoter and mediate transcriptional responsiveness
to fatty acids and to drugs speciﬁcally activating both PPAR
subtypes. This occurs due to the presence of a PPAR-
responsive element in the proximal region of the UCP3 pro-
moter[65,78].Moreover,RXRactivators(rexinoids)activate
UCP3 gene transcription via ligand-dependent activation of
the RXR moiety of the PPARα/RXR or PPARδ/RXR het-
erodimers binding to the promoter. Interestingly, PPAR-
dependent activation of the UCP3 gene requires MyoD,
which acts as a transcription factor permissive for basal and
PPAR-dependent regulation of the UCP3 gene in muscle
cells. Coactivators such as p300 mediate this functional re-
lationship between MyoD and PPAR-dependent regulation
of the UCP3 gene [78].
The control of UCP3 gene transcription by PPAR/RXR
heterodimers, which retain the capacity for ligand-depend-
ent activation of the RXR moiety [78], explains the sensitiv-
ity of UCP3 gene expression to 9-cis retinoic acid in myo-
genic cells [69] and to dietary vitamin A supplementation
or acute retinoic acid-treatment [79]. However, it should be
taken into account that RAR-dependent pathways of regula-
tion are also active on the UCP3 gene promoter [69]. On the
other hand, although RXR has been proposed to be able to
mediate transcriptional regulation through binding itself to
fatty acids, UCP3 gene promoter studies appeared to exclude
the possibility that RXR plays this role at the UCP3 gene
[65].
Moreover, dozens of reports in recent years have indi-
cated a positive association between a C to T polymorphism
in the human UCP3 gene promoter and body weight distur-
bancesorinsulinresistance[80].ThisCtoTchangehasbeen
reported to modulate the relative levels of UCP3 transcripts
in muscle from Pima Indians [81]. UCP3 promoter analysis
revealed that the site of this polymorphism is adjacent to the
PPARα/δ-responsive element (see Figure 2), although no di-
rect eﬀects on promoter activity dependent on the presence
of C or T have been demonstrated to date [78].6 PPAR Research
On the other hand, the potential role of PPARγ in the
control of UCP3 in the muscle or heart is unclear. Con-
tradictory results have been reported on the action of thi-
azolidinediones on UCP3 gene expression in myogenic cells,
from inhibition [82] to stimulation [83]. Treatment with thi-
azolidinediones “in vivo” also led to variable eﬀects depend-
ing on the type of thiazolidinedione or the length of treat-
ment [33, 57, 84, 85]. Mice with a muscle-speciﬁc PPARγ
deletion show unaltered UCP3 gene expression [86]. In these
mice, treatment with rosiglitazone or troglitazone leads to
a reduction in UCP3 mRNA levels whatever the genotype,
thus indicating that the eﬀects of thiazolidinediones on the
UCP3 gene are likely to be PPARγ-independent [86]. This is
in agreement with UCP3 gene promoter studies indicating a
lack of sensitivity to PPARγ at least in the context of myo-
genic cells [65, 78].
In summary, PPARα and PPARδ are major regulators of
UCP3 gene expression in skeletal muscle and the heart, as
they appear to mediate the powerful physiological regulation
of these genes by fatty acids. The physiological role of UCP3
in relation to fatty acids is unclear. However, the available
data indicate that, when the muscle or heart is challenged by
an overload of fatty acids, UCP3 may act to favor fatty acid
metabolism in such a way that minimizes toxicity and mi-
tochondrial production of reactive oxygen species. Pharma-
cological activation of PPARα and PPARδ via ﬁbrates may
then favor these physiological functions in muscle. Type 2
diabetes, and ultimately obesity or metabolic syndrome, may
be related to the appearance of insulin resistance in muscle
as a consequence of defective handling of fatty acids. The ac-
tion of PPARs on the control of UCP3 gene expression may
represent a potential tool to prevent the negative eﬀects of
high exposure of muscle to fatty acids, although further re-
search will be required to more ﬁrmly establish this possibil-
ity.
FATTY ACIDS AND PPARS IN THE CONTROL OF
UCP2 GENE EXPRESSION IN SKELETAL
MUSCLE AND HEART
The expression of the UCP2 gene shares with UCP3 being
stimulated by fatty acids in skeletal muscle and heart, as
well as being a target of PPARα and PPARδ-dependent ac-
tivation in these tissues. However, several evidences indicate
that fatty acid-dependent activation of UCP2 gene transcrip-
tion is more complex, and involves also PPARα and PPARδ-
independent mechanisms. The relative roles of these PPAR-
independent mechanisms may be diﬀerent depending on the
tissue in which UCP2 is expressed, and, for instance, they
are especially relevant in heart or other tissues such as the
liver (see below). Direct eﬀects of PPARδ activators on UCP2
mRNA expression have been demonstrated in human my-
otubes [87], and direct analysis of regulation of the UCP2
genepromoterinmusclecellsindicatedthatPPARγ andtheir
ligandsinducepromoteractivity.However,nodirectbinding
of PPARγ could be detected, thus raising the possibility of an
indirect eﬀect [88].
PPARS IN THE CONTROL OF UCP3 AND UCP2
GENE EXPRESSION IN ADIPOSE TISSUES
Aspreviouslymentioned,UCP3ishighlyexpressedinbrown
adipose tissue and to a very minor extent in white fat,
whereas UCP2 is expressed in both types of adipose tissue.
As in the muscle or heart, drugs activating PPARα or PPARδ
induce UCP3 gene expression in brown fat, both as a result
of acute, single-dose treatment, and after chronic treatment
[33, 34].
The high expression of PPARγ in adipose tissues, in con-
trast with that in muscle, together with the sensitivity of the
UCP3 and UCP2 genes to the PPARα and PPARδ subtypes
raised the question of the capacity of PPARγ activation to af-
fectUCP3andUCP2geneexpressioninadiposecells.Theef-
fects of chronic treatment with rosiglitazone, a thiazolidine-
dione capable of activating PPARγ,h a v eb e e nr e p o rt e dt oi n -
volve a robust induction [89], a moderate increase [90]o r
even no change [33] in UCP3 mRNA levels in white adi-
pose tissue. The reasons for these discrepancies are unclear
and diﬀerent doses or rodent species and strains used may
be the basis of the diﬀerent ﬁndings. It should be noted that,
as mentioned for UCP1, any treatment of mice or cells driv-
ing the white fat phenotype into a brown fat-like phenotype
or generally promoting brown fat diﬀerentiation may result
in increased UCP3 gene expression in white adipose depots.
This UCP3 mRNA induction in white adipose depots could
be just one more symptom of the acquisition of “brown fat-
like” features, considering the plasticity of adipose depots in
rodents. Rosiglitazone treatment “in vivo” may exert these
overall eﬀects and its action on UCP3 gene expression may
depend ontheextent ofalterationsinthebrownversuswhite
pattern of gene expression.
Concerning UCP2, chronic thiazolidinedione treatment
in rodents has also been reported to increase [33]o rt on o t
aﬀect [90] UCP2 gene expression in white fat, whereas in-
creased expression of UCP2 mRNA has been observed in
subcutaneous adipose tissue from human patients treated
with rosiglitazone [91]. A moderate induction of UCP2
mRNA has also been reported in cell cultures of white adipo-
cytes [92]. In the context of white adipogenic cell lines,
PPARγ and their ligands induce UCP2 promoter activity in
the absence of direct binding and via E-box elements in the
proximal region of the promoter [88]. In brown adipocytes,
r o s i g l i t a z o n ea sw e l la sa c t i v a t o r so fP P A Rc o m m o nt ot h e
PPARα and PPARδ subtypes induce UCP2 mRNA expres-
sion. However, 9-cis retinoic acid and selective activators of
RXR were the most powerful in inducing UCP2 mRNA ex-
pression, most probably due to their capacity to activate the
dimers of RXR with PPARs or with other permissive nuclear
receptors [93].
Ontheotherhand,adiposetissuescontainlargeamounts
ofendogenoustriglycerides,whicharecapableofresultingin
the local generation of free fatty acids after lipolysis. PPAR
receptors can provide a mechanism for responsiveness of
UCP2 and UCP3 expression to intracellularly derived fatty
acids. Thus, a cross-talk between adrenergic regulation of
adipose tissue lipolysis and PPAR mechanisms of inductionFrancesc Villarroya et al. 7
of gene expression of UCP2 and UCP3 may occur as men-
tioned above for UCP1, especially in response to noradren-
ergic stimulus in brown adipocytes.
ROLE OF PPARS IN THE CONTROL OF UCP2
GENE EXPRESSION IN PANCREATIC β-CELLS
Studies in UCP2-null mice have revealed that UCP2 exerts
substantial negative control over glucose-stimulated insulin
secretion [94]. Thus, UCP2 expression may play an impor-
tant role in the pathogenesis of diabetes. UCP2 expression is
stimulated by high glucose and/or high free fatty acid levels
both “in vivo” and “in vitro”, as well as being increased in
animal models of type 2 diabetes. On the other hand, a ge-
netic deﬁciency of UCP2 improves β-cell function in animal
models as well as in “in vitro” models of glucotoxicity and
lipotoxicity in β-cells reviewed in [95].
It has been demonstrated that exposure to fatty acids in-
creases transcription of the UCP2 gene in human and rodent
cells representative of adipocytes and myocytes (see above),
as well as in pancreatic β-cell-derived cell lines (INS-1 cells).
An enhancer region has been identiﬁed between −86 to −44
of the mouse UCP2 gene. This enhancer contains Sp1 ele-
ments, sterol regulatory element (SRE), and double E-box
elements all clustered together and is responsible for basal
andfattyacid-stimulatedtranscription.Theresponsetofatty
acids appears to be mediated by sterol regulatory element
binding proteins (SREBPs) binding to the SRE [96]. This en-
hancer is not conserved in the human UCP2 promoter but
two E-box motifs at −911 to −906 and −743 to −738 have
been identiﬁed as being responsible for the SREBP activa-
tion of human UCP2 gene transcription in INS-1E cells [97].
However, despite the important pathophysiological implica-
tions, the mechanisms by which chronic exposure to fatty
acids increases UCP2 expression in pancreatic β-cells have
notbeencompletelycharacterized,andinadditiontoSREBP
proteins,PPARreceptorsandtheGprotein-coupledreceptor
GPR40 could be implicated.
All PPAR subtypes are expressed in pancreatic β-cells
[98]. Although their roles in β- c e l lf u n c t i o nr e m a i np o o r l y
understood, several lines of evidence suggest that PPARα
may be implicated in the modulation of insulin secretion:
(i) fatty acids stimulate the expression of PPARα and its tar-
get genes in islets [98]; (ii) cloﬁbrate treatment or PPARα
overexpression in INS-1cells induce UCP2 expression, in-
crease fatty acid oxidation, and decrease basal and glucose-
stimulated insulin secretion [99]; (iii) in wild-type mice,
starvationincreasesisletPPARαandUCP2expression,which
maycontributetodecreasedinsulinsecretion,whereasfasted
PPARα null-mice display increased plasma insulin levels
andenhancedglucose-inducedinsulinsecretion[100].Thus,
pancreatic PPARα signaling appears to be signiﬁcant “in
vivo” and, when PPARα is activated due to elevated fatty acid
levels, as in obesity, it may contribute to glucose intolerance
and β-cell dysfunction.
Contradictory data have been reported on the eﬀects of
PPARγ on UCP2 expression in β-cells. It has been described
that overexpression of PPARγ causes upregulation of UCP2
expression and suppresses glucose-stimulated insulin secre-
tion [101]. In contrast, the increase in UCP2 expression in-
duced by chronic exposure of pancreatic islets to palmitate
is prevented by addition of rosiglitazone, and this treatment
also normalizes insulin secretion [102]. No direct binding of
PPARγ to the enhancer in the mouse UCP2 gene has been
observed. Thus, the eﬀects on UCP2 expression may be pro-
duced by indirect mechanisms [88].
GPR40 has been recently identiﬁed as a G protein-
coupledreceptorselectivelyexpressedinβ-cellsandactivated
by fatty acids. GPR40-null mice develop neither hyperin-
sulinemia nor glucose intolerance when challenged with a
chronic high-fat diet. In contrast, transgenic mice overex-
pressing GPR40 in β-cells are glucose intolerant and show
impaired glucose-stimulated insulin secretion. In addition,
in pancreatic islets of these mice, the mRNA levels of PPARα,
SREBP1c, and UCP2 are increased. Thus GPR40 may play
a key role in the development of diabetes and could be im-
plicated in the upregulation of PPARα signaling in insulin-
resistant conditions [103].
PPARS AND UCP GENE EXPRESSION IN THE LIVER
Theliver istheorganin whichexpression ofUCPsis thelow-
est, in basal conditions. Only minor expression of UCP2 can
be detected in the adult liver, and it is mainly due to high
expression in Kupﬀer cells [104]. However, in situations of
metabolicstress,UCP2expressionisinducedintheliver,and
enhanced expression appears mainly in hepatocytes [105].
Increased UCP2 mRNA expression in the liver has been
reported in response to starvation, but also in obese, leptin-
deﬁcient conditions, and in rodents treated with a high-fat
diet[35,106,107].However,theincreaseinUCP2expression
is not necessarily related to obesity and insulin resistance,
as a high ﬁsh-oil diet, which does not result in signiﬁcant
weight gain, is more eﬀective in increasing UCP2 levels than
is a high saﬄower oil-based diet [108]. Thus, it has been sug-
gested that fatty acids might be key factors determining the
controlofUCP2expressionintheliver,regardlessofwhether
they are associated with high lipolysis in situations of starva-
tion or the opposite, high fatty acid levels as in obesity. PPAR
signaling is a candidate for mediation of this regulation. In
fact, PPARα expression increases in the liver during fasting
[35] and in several models of murine obesity [106]. Chronic
treatment of rodents with PPARα agonists such as fenoﬁ-
brateorWy14643increaseshepaticUCP2mRNAexpression
[105–108]. UCP2 mRNA levels are also upregulated in cul-
tured hepatocytes in response to polyunsaturated fatty acids,
Wy 14643 or fenoﬁbrate [105, 109]. However, there is some
data suggesting the existence of signaling mechanisms other
thanthroughPPARα.Forinstance,theincreaseinliverUCP2
expression induced by starvation is preserved in PPARα-null
animals [35]. It has been suggested that PPARδ may con-
tribute to the regulation of UCP2 gene expression in PPARα-
deﬁcientmice[110].RegulationviaPPARγ mustbealsocon-
sidered as UCP2 is induced by the PPARγ activator troglita-
zone in cultured hepatocytes. However, the PPARα activa-
tor Wy 14643 was a more powerful inducer of UCP2 gene8 PPAR Research
expression in hepatic cells [109]. Despite the very low ex-
pression of PPARγ in the liver under basal conditions, it is
increased in obesity, in insulin resistance, and after a high-
fat diet [106, 107]. PPARγ is highly expressed in liver from
PPARα null-mice fed a high-fat diet, and this is associated
withan induction of UCP2 gene expression [107]. Moreover,
adenoviral-induced overexpression of PPARγ in the liver of
PPARαnull-micecausesadramaticincreaseinUCP2mRNA
levels [107]. Thus, the available data suggests a major role
for PPARα in the regulation of UCP2 expression in the liver
whereas, in some particular pathophysiological situations,
additional pathways may be involved; mainly PPARδ and
PPARγ as well as possibly other transcription factors.
Among UCP gene regulation in the liver, most attention
has been focused in UCP2, as other UCP genes are silent
in this tissue. However, it has been described that chronic
fenoﬁbrate administration to mice or rats induces “de novo”
UCP3 expression in the liver [108, 111]. Recently, it has been
demonstrated that the appearance of UCP3 transcripts is ac-
companied by the presence of the UCP3 protein in the mi-
tochondrial fraction. In fact, genes involved in fatty acid oxi-
dation and preferentially expressed in muscle, such as carni-
tine palmitoyl-transferase I-b, are also induced in the liver
as a consequence of fenoﬁbrate treatment [112]. Interest-
ingly, although this treatment also upregulates UCP2 mRNA
levels, UCP2 protein was not detectable, most likely due to
the presence of an inhibitory post-translational mechanism.
Thus, in the absence of UCP2 protein, the uncoupling eﬀects
detected in liver mitochondria after fenoﬁbrate treatment
are presumably attributable to UCP3 [112]. The results of
chronic fenoﬁbrate treatment stress the importance of post-
translational mechanisms of regulation of UCP2 gene ex-
pression in the liver, in agreement with previous reports in
other systems [113].
CONCLUSIONSAND PERSPECTIVES
Intensive research eﬀorts over recent decades have estab-
lished that PPARs are major controllers of UCPs gene ex-
pression. Diﬀerent PPAR subtypes are preferentially involved
in the control of each UCP gene depending on the UCP
gene or the main tissue of expression. The control of UCPs
genes by PPAR subtypes either provides tissue-speciﬁc reg-
ulation of UCPs gene transcription, as seen in UCP1 con-
trolbyPPARγ, or regulates the responsiveness of UCPs genes
to metabolic challenges, as seen in the control of the UCP3
gene by PPARα and PPARδ in the muscle and heart. The pre-
cise identiﬁcation of mechanisms or PPAR subtypes involved
in the control of UCP genes may be of utmost relevance in
the foreseeable pharmacological approaches aimed at inﬂu-
encing metabolic disturbances involving skeletal muscle (ie,
UCP3 gene control) or at modulating pancreatic insulin se-
cretion (ie, UCP2 control in the pancreas). This research can
be expected to have a high impact in the near future in rela-
tion to obesity and metabolic syndrome. Other issues poorly
explored to date, as for instance the role of PPAR-dependent
regulationofUCP2geneexpressioninmacrophages,cellsex-
pressing high levels of UCP2 [114] and highly sensitive to
PPARs [115], would be important to further establish the
mechanisms of PPAR action in inﬂammatory processes, in-
cluding the chronic inﬂammation present in obesity. A new
transgenic mouse model with a speciﬁc deletion of PPARγ in
macrophages has already been developed [116] which may
be useful in exploring the role of PPARγ in this cell type. We
should expect much new data in the next years on the role of
PPAR subtypes in obesity and metabolic syndrome, and on
the role of disturbances in PPAR-mediated control of UCPs
gene expression in these pathologies.
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